A 12-year-old girl with Fanconi anaemia (FA) received a bone marrow transplant from her HLA-identical brother following conditioning with cyclophosphamide (20 mg/kg), thoraco-abdominal radiation (TAI) (4 Gy) and equine anti-thymocyte globulin (ATG) (90 mg/kg). Engraftment was delayed and initially tenuous, and was followed by mixed chimerism (MC) over a follow-up period of 2 years. DNA analysis of engraftment was performed on whole peripheral blood and on separated granulocytes, B and T lymphocytes using PCR detection of CA tandem repeat polymorphisms. At 10 weeks post BMT, granulocytes were predominantly donor, but B and T lymphocytes recipient, in origin. Over the subsequent 90 weeks, granulocytes and B lymphocytes were donor-derived, whilst T cells showed persistent MC but with an increasing donor component. Marrow haemopoietic function (Hb, ANC and platelet count) improved gradually in parallel with a rise in the proportion of donor lymphocyte engraftment. We postulate that a population of recipient lymphocytes survived conditioning and in turn delayed the development of full donor chimerism. Although transient MC has been described after allogeneic BMT in FA, its association with delayed engraftment, and persistence for more than 1 year post BMT, has not been documented clearly. Keywords: mixed chimerism; delayed engraftment; Fanconi anaemia; bone marrow transplantation; child Allogeneic BMT is currently the only curative treatment for bone marrow failure in Fanconi anaemia (FA). In patients undergoing BMT, host lymphoid and haemopoietic cells usually decline progressively, resulting in replacement by donor cells within 1-2 months of transplantation. We report a case of FA who had delayed engraftment followed by persistent, mixed chimerism (MC) after receiving a BMT from an HLA-identical sibling donor. 
Case report
A 7-year-old girl presented with a recent history of increased bruising. She had no congenital abnormalities or dysmorphic features apart from clinodactyly, and her growth was normal. Her full blood count (FBC) showed Hb 9.0 g/dl, mean corpuscular volume (MCV) 106 fl, WBC 5.3 (ANC 1.8) × 10 9 /l and platelets 25 x 10 9 /l. Chromosomal fragility in response to mitomycin-C was increased in comparison to an age-matched control, establishing the diagnosis of FA. She was observed closely as her FBC gradually deteriorated, and by 12 years of age she had received three blood and two platelet transfusions within a 14 month period. Since she had an older HLA-identical sibling donor, in whom FA had been excluded by a normal FBC and chromosomal fragility studies, she proceeded to allogeneic BMT. She was conditioned with low-dose cyclophosphamide (CY) (5 mg/kg on days −5 to −2, total dose 20 mg/kg), thoraco-abdominal irradiation (TAI) (4 Gy) on day −1, and equine anti-thymocyte globulin (ATG) (30 mg/kg on days −5 to −3, total dose 90 mg/kg). GVHD prophylaxis consisted of cyclosporine (CYA) only. She received unmanipulated bone marrow (nucleated cell dose 2.6 × 10 8 /kg). The recipient was CMV negative but the donor CMV IgG positive. On day +8, the CMV PCR assay was positive in peripheral blood. She was started on ganciclovir 5 mg/kg/dose twice daily for 1 week and then 2.5 mg/kg/dose twice daily for a further 11 days. CMV was not isolated from any site, the antigenaemia test remained negative and PCR became negative from day +20. By day +7, her WBC was 0.5 × 10 9 /l. Soon thereafter she developed a maculopapular rash with histological features consistent with acute GVHD grade II (skin stage 3). She was treated with methylprednisolone 500 mg/m 2 /day for 3 days with good effect. However, the WBC count remained Ͻ0.5 × 10 9 /l until day +21 when she was started on G-CSF 5 g/kg/day. Her ANC was Ͼ0.5 × 10 9 /l by day +28. After the ANC had been Ͼ1.0 × 10 9 /l for 2 consecutive days, G-CSF was stopped, but the ANC fell rapidly to 0.3 × 10 9 /l. G-CSF 5 g/kg three times weekly was restarted, and she was discharged on day +42, although still needing regular platelet transfusions. There was no evidence of haemolysis.
Cytogenetic and DNA analysis of engraftment was performed (see below), and the results at 10 weeks post BMT were interpreted as showing that the myeloid series was predominantly donor derived, while the lymphoid series was mainly recipient derived (Table 1 and Figure 1 ). There was felt to be a danger of secondary graft rejection and immunosuppression was considered. First, she was given a trial without G-CSF and encouragingly her ANC stabilised at Ͼ0.5 × 10 9 /l. Subsequently, over 2 years follow-up, she has remained clinically well and her FBC has improved slowly. Her blood group (group A positive pre-transplant) changed to that of the donor (group O positive) by 16 weeks post BMT, and has remained of donor origin subsequently.
Analysis of post-BMT chimerism
DNA analysis using PCR detection of the CA tandem repeat polymorphism at D5S346 (DP1) was performed using the following oligonucleotide primers: 5ЈACTCACTCTAGTGATAAATCGGG (forward) and 5ЈAGCAGATAAGACAGTATTACTAGTT (reverse). The forward primer was 5Ј end labelled using ␥ 32 P-ATP and polynucleotide kinase. The PCR reaction consisted of 1-2 l DNA, each primer at 10 m, 200 m of each dNTP, 1 U Taq polymerase and the supplier's reaction buffer (Promega, Madison, WI, USA) in a total volume of 10 l. The amount of DNA per reaction was typically 20-100 ng, but concentrations were not accurately determined following extraction from small numbers of cells. The PCR conditions were as follows: denaturation at 94°C for 5 min and then 30 cycles of 91°C for 1 min, 57°C for 1 min, 72°C for 2 min followed by an elongation step of 72°C for 10 min. PCR generated fragments were separated by electrophoresis on 6% denaturing gels and detected by autoradiography. Alleles were scored using a numbering system where the largest was denoted allele 1 (estimated at 116 base pairs) and the smallest allele 3 (102 base pairs); allele 2 was estimated to be 110 base pairs. Previous in-house experiments have revealed a lower limit of detection of a donor or recipient allele of 5% in this system. When donor or recipient alleles appear similar in intensity, their relative contributions are 50 Ϯ 15%. Before transplant the patient typed 1-2 and the donor 2-3. Six weeks post BMT the patient showed a predominance of donor alleles (2-3), with only a trace of host allele 1 (Figure 1 ). Cytogenetic examin- ation, however, showed no evidence of male (donor) karyotype in any of the 50 cells examined after PHA stimulation (Table 1) . In view of the conflicting information from DNA and cytogenetic analysis of whole blood, it was decided to perform DNA analysis on separated peripheral white blood cells. Mononuclear cells (lymphocytes and monocytes) were separated from granulocytes using a Ficoll density gradient. Magnetised polystyrene beads (Dynabeads; Dynal, Oslo, Norway) coated with anti-CD3 (1 × 10 7 beads/ml) were then incubated with the mononuclear cells (2 × 10 6 /ml), with subsequent removal of the bound T lymphocytes by a magnet. This was repeated for B cells using Dynabeads coated with CD19. Quality control to ensure T and B lymphocyte preparations of Ͼ95% purity was achieved by staining pre-and post-separation samples with FITC-conjugated anti-CD3 and phycoerythrin-conjugated anti-CD19 monoclonal antibodies (Becton Dickinson, San Jose, CA, USA), and analysis by FACS scan (Becton Dickinson). Light microscopy was used to detect unbound cells in the bead fractions. The remaining cells included monocytes and natural killer cells.
Ten weeks post BMT, the patient had predominantly donor alleles in granulocytes but only recipient alleles in B and T lymphocytes. However, over the next 90 weeks, as her FBC improved, sequential DNA analysis revealed gradual conversion to full donor engraftment in the myeloid and B cell series while the T lymphocytes continued to show MC, albeit with an increasing proportion of donor alleles (Table 1 and Figure 1 ). Cytogenetic analysis demonstrated an increasing proportion of PHA-stimulated cells (ie T cells) with a male (donor) karyotype (Table 1) .
Discussion
The natural history of FA in most patients is death from progressive pancytopenia due to bone marrow failure, usually during the second or third decade of life. Currently, BMT is the only curative treatment for marrow failure in FA. If performed using marrow from an HLA-matched sibling donor, BMT offers a very good prognosis with Ͼ80% survival reported. Our patient received BMT from her HLA-identical brother after conditioning with low-dose CY, TAI and ATG. She developed subclinical CMV infection and grade II acute GVHD early post BMT. Engraftment was delayed and initially uncertain, and was followed by persistent MC. Over follow-up of 2 years post BMT, the degree of donor engraftment increased gradually across both the haemopoietic and lymphoid cell lineages. The early CMV infection, or its treatment with ganciclovir, may have contributed to the poor early graft function, but it is less likely that either would have caused long-term MC. Minor ABO incompatibility, although present, is unlikely to have delayed engraftment in the absence of haemolysis.
In the majority of patients undergoing BMT, host cells decline progressively, resulting in more or less complete replacement by donor lymphoid and haemopoietic cells by about 2 months post BMT. The incidence of graft failure and MC, rather than full donor chimerism, is much higher following transplantation with T cell-depleted BM than with use of whole marrow. 3 It is likely that donor T cells help eliminate any surviving host lymphocytes, facilitating donor engraftment. However, MC has been detected by PCR in 44% of T non-cell-depleted BMT patients. 4 In our patient, the relatively non-intensive conditioning treatment did not eradicate all recipient lymphocytes, and these may have inhibited engraftment and allowed the development of MC, particularly in the context of a comparatively low cell dose. The pronounced heterogeneity of Fanconi anaemia patients suggests that it is likely to be difficult to identify a conditioning regimen that is ideal for all patients.
The clinical significance of MC following BMT is uncertain. There are several descriptions of persistent MC after HLA-identical sibling BMT for acquired aplastic anaemia, 5, 6 but, in contrast, reports of persistent MC in FA are rare. Surviving recipient cells after BMT may either reject donor marrow cells, or become tolerant to them and con-tribute to the establishment of MC. 7 Of 19 FA patients published by Socie et al, 8 six showed MC. Residual recipient cells were detected only transiently (at a maximum of 100 days post BMT) in five patients, but one showed a persistence of recipient cells up to day +330 and developed 'bone marrow failure and late graft rejection'. In a series of thalassaemic patients, all those with MC level 3 (Ͼ30% recipient cells) suffered graft rejection within 1 year post BMT. 9 In a large series of patients with SAA, those with MC had a significantly higher risk of graft rejection than those who were complete chimeras. 10 MC stability, rather than the proportion of host cells, may be more important for the continuation of clinical response and haematological function. 4 Potentially, donor cells can gradually increase in number and contribute to the eradication of remaining recipient cells. Alternatively, an increase in recipient cells may predict patients at higher risk of secondary graft failure. Post-BMT FA patients with a significant proportion of host haematopoietic cells may also remain at higher risk for the development of leukaemia.
In summary, persistent MC after HLA-identical sibling BMT for FA has been described rarely. However, the prolonged survival of recipient lymphocytes in our patient was associated with delayed and initially tenuous engraftment, but her graft haemopoietic function improved as the proportion of donor lymphocytes, especially T cells, increased.
